Watson Completes Actavis Acquisition

(Thomson Reuters ONE) -



NEWS RELEASE

                                       CONTACTS:      Investors:
                                       Lisa
DeFrancesco
                                         (862) 261-7152

                                       Media:
                                       Charlie Mayr
                                             (862) 261-8030


Watson Completes Actavis Acquisition

- Creates 3(rd) largest global generics company with presence in 60+ markets -
- $8.0+ billion anticipated pro forma combined 2012 revenue -
- Combined management structured to immediately maximize combination value -
(

)
PARSIPPANY, N.J. - October 31, 2012 - Watson Pharmaceuticals, Inc. (NYSE: WPI)
today announced that it has completed the acquisition of the Actavis Group for
EUR 4.25 billion.  The combination creates the world's third largest generic
pharmaceutical company, with anticipated pro forma combined 2012 revenues in
excess of $8 billion.

Watson funded the transaction through a combination of $1.8 billion in term loan
borrowings and the issuance of $3.9 billion in senior unsecured notes.  The
Company said the transaction is immediately accretive to non-GAAP earnings,
before synergies.  The Company also noted that the strong cash flows of the
combined business are expected to permit rapid pay down of debt.

"Today we unite two powerful, profitable and rapidly growing companies into one
exceptional global business.  As a result of accelerated integration planning,


we will immediately begin to maximize the exceptional financial and commercial
value of this combination," said Paul Bisaro, President and CEO of Watson.
 "Over the past several months we have defined and communicated internally the
Global Generics, R&D and Operations and Shared Services management structures
and today begin operations as a combined company.  We also begin the immediate
execution of our Day 1 through Day 100 integration strategies to support
continued growth, while optimizing our global structure and capturing our
projected synergies.  I am confident that working together, the 17,000 people of
our new company will now be focused on the seamless integration of the company
for strong and sustainable growth."

"With the acquisition complete, we now have the generic assets in place that
will power our continued organic growth, and generate strong cash flow to
support the rapid pay-down of debt, which will allow us to continue to focus on
future investments to enhance all of our businesses, particularly our Global
Brands and Biosimilars businesses.  Watson plans to host Investor Day 2013 in
January to provide a more comprehensive review of the combined business."

Significant Synergies Expected
Watson continues to expect $300 million in annual cost synergy savings from the
Actavis acquisition within three years.  These synergies are comprised of SG&A,
R&D, corporate, purchasing and raw material supply savings.

Transaction Financing Favors Rapid Deleveraging
The acquisition was funded through a combination of $1.8 billion in term loan
borrowings at an average rate of three-month libor plus 150 basis points and the
issuance of $3.9 billion in senior unsecured notes. The overall combined cost of
debt for the acquisition was approximately 2.9 percent.  The combined company is
expected to generate strong free cash flow in 2013, which favors rapid
deleveraging.

Review of the Benefits of the Acquisition
This acquisition combines two growing, successful and highly profitable
companies, and substantially completes Watson's expansion as a leading global
generics company.  The combined Company begins operations with a defined global
management structure and aggressive integration execution strategies in place to
focus on organic growth and rapid achievement of synergies.

Expanded Global Geographic Footprint
The combined company has operations in more than 60 countries, with top 10
positions in more than 33 markets including the U.S., U.K., Canada, Australia,
Nordics and Russia. With this global footprint, the combined company has an
extensive platform for strong, future organic growth.  The strongest growth
regions for the new company will be the U.S., Central and Eastern Europe and
Russia and in Southeast Asia and Australia.  The Company is also the fastest
growing generic pharmaceutical company in Western Europe, where growth is
outpacing the overall market.  The combined company will be geographically
diverse, with approximately 40 percent of its revenues coming from outside of
the U.S.

Expanded Portfolio and Development Pipeline
The combined Company has an industry leading global product portfolio of over
750 molecules offered in more than 1,700 different combinations and dosage
forms.  The Company also has expanded its core leadership position in oral solid
modified release and transdermal products, as well as semi-solids, liquids and
injectables.  The U.S. pipeline includes approximately 180 unique ANDAs pending
at the FDA, including 47 First-to-Files, of which we believe over 30 are
exclusive.  Outside of the U.S., the current pipeline includes more than 2,000
marketing authorizations pending approval and, globally, greater than 600 new
development projects are underway covering multiple dosage forms.

Expanded Global Supply Chain
The Company has an expansive, diversified global supply chain with various
technological capabilities, including the ability to manufacture more than 40
billion dosages worldwide.  The combined company has the expertise to develop
solid dosage, modified release, patch, gel, liquid, semi-solid and injectable
products for all of its global markets.

Conference Call and Webcast Information
Watson plans to discuss the close of the acquisition on its third quarter
earnings conference call scheduled for November 1, 2012 at 8:30 a.m. Eastern
Time.
The dial-in number to access the call is (877) 251-7980, or from international
locations, (706) 643-1573.  The Conference ID is 37197625.

A taped replay of the conference call will also be available beginning
approximately two hours after the call's conclusion and will remain available
through 12:00 midnight Eastern Time on November 15, 2012.  The replay may be
accessed by dialing (855) 859-2056 and entering the same Conference ID above.
 From international locations, the replay may be accessed by dialing (404)
537-3406.  To access the webcast, go to Watson's Investor Relations Web site at
http://ir.watson.com.

Additional resources are available at www.multivu.com/mnr/58370-watson-
pharmaceuticals-acquires-actavis-group.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. (NYSE: WPI) is a global, integrated specialty
pharmaceutical company focused on developing, manufacturing and distributing
generic, brand and biosimilar products.  The Company has global and U.S.
headquarters in Parsippany, New Jersey, USA, and international headquarters in
Zug, Switzerland.

Watson is the world's third-largest generics manufacturer, with more than 750
products marketed globally through operations in more than 60 countries.
Watson's global branded pharmaceutical business develops and markets products
principally in Urology and Women's Health, and is committed to developing and
marketing biosimilars products in Women's Health, Oncology and other therapeutic
categories.  In addition, Watson is the fourth-largest U.S. generic
pharmaceutical product distributor through its Anda, Inc. business, and also
develops and out-licenses generic pharmaceutical products outside of the U.S.
through its Medis third-party business.

For press release and other company information, visit Watson Pharmaceuticals'
Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to Watson's estimated or
anticipated future results or other non-historical facts are forward-looking
statements that reflect Watson's current perspective of existing trends and
information as of the date of this release. For instance, any statements in this
press release concerning prospects related to Watson's strategic initiatives,
product introductions and anticipated financial performance are forward-looking
statements. It is important to note that Watson's goals and expectations are not
predictions of actual performance. Watson's performance, at times, will differ
from its goals and expectations. Actual results may differ materially from
Watson's current expectations depending upon a number of factors affecting
Watson's business. These factors include, among others, the inherent uncertainty
associated with financial projections; successful integration of the Actavis
acquisition and the ability to recognize the anticipated synergies and benefits
of the Actavis acquisition; the difficulty of predicting the timing and outcome
of pending or future litigation and government investigations and risks that an
adverse outcome in such litigation or investigations could render Watson liable
for substantial damages or penalties; risks that resolution of patent
infringement litigation through settlement could result in investigations or
actions by private parties or government authorities or agencies; the impact of
competitive products and pricing; risks related to fluctuations in foreign
currency exchange rates; periodic dependence on a small number of products for a
material source of net revenue or income; variability of trade buying patterns;
changes in generally accepted accounting principles; risks that the carrying
values of assets may be negatively impacted by future events and circumstances;
the timing and success of product launches; the difficulty of predicting the
timing or outcome of product development efforts and regulatory agency approvals
or actions, if any; risks and uncertainties normally incident to the
pharmaceutical industry, including product liability claims and the availability
of product liability insurance on reasonable terms; market acceptance of and
continued demand for Watson's products; difficulties or delays in manufacturing;
the availability and pricing of third party sourced products and materials;
successful compliance with governmental regulations applicable to Watson's
facilities, products and/or businesses; changes in the laws and regulations,
including Medicare, Medicaid, and similar laws in foreign countries affecting,
among other things, pricing and reimbursement of pharmaceutical products and the
settlement of patent litigation; and such other risks and uncertainties detailed
in Watson's periodic public filings with the Securities and Exchange Commission,
including but not limited to Watson's Annual Report on Form 10-K for the year
ended December 31, 2011 and Watson's Quarterly Report on Form 10-Q for the
period June 30, 2012. Except as expressly required by law, Watson disclaims any
intent or obligation to update these forward-looking statements.



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Actavis via Thomson Reuters ONE
[HUG#1654312]




Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 01.11.2012 - 01:08 Uhr
Sprache: Deutsch
News-ID 753844
Anzahl Zeichen: 12713

Kontakt-Informationen:
Stadt:

Zug

Kategorie:

Wirtschaft (allg.)

Diese Pressemitteilung wurde bisher 145 mal aufgerufen.

Alle Meldungen von Actavis